Esperion Therapeutics has entered into a definitive agreement to acquire Corstasis, a privately held company. This acquisition is intended to enhance Esperion's existing cardiovascular franchise. Financial terms of the transaction were not disclosed.

The acquisition is expected to be completed in the first quarter of 2024, subject to customary closing conditions. Esperion stated that the integration of Corstasis is anticipated to complement its current portfolio and strategic objectives within the cardiovascular therapeutic area.

Further details regarding the transaction and its implications are expected to be provided at a later date.

Key Takeaways

• Esperion Therapeutics plans to acquire Corstasis.
• The acquisition aims to expand Esperion's cardiovascular franchise.
• The deal is anticipated to close in the first quarter of 2024.
• Financial terms have not been disclosed.

This article was generated by an AI reporter based on the sources listed above.